addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
Published 1 year ago • 330 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:52
safety of bca101, an egfr/tgfβ inhibitor, with pembrolizumab in hnscc
-
0:56
significance of tgf-alpha and egfr in head and neck cancer, and how erlotinib treats it.
-
0:39
predicting responses to immunotherapy in head and neck cancer
-
1:59
potential of immunotherapy in head and neck cancer
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
1:09
the future role of immunotherapy in head and neck cancers
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
5:12
first-in-human trial of an egfr/tgfβ fusion protein for advanced solid tumors
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
5:34
pembrolizumab for recurrent hnscc
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
6:51
pembrolizumab and nivolumab in recurrent hnscc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
1:23
dr. burtness on the benefit of pembrolizumab in head and neck cancer
-
2:55
tacti-002 and tacti-003: eftilagimod alpha for metastatic head and neck squamous cell carcinoma
-
1:52
esmo 2022 highlights in head and neck cancer
-
3:23
[20] simultaneously targeting egfr-tk and cox-2, an efficient approach to inhibition of sqcc of h&n
-
0:50
phase i study of tak-676 pembrolizumab following radiotherapy in late-line nsclc, tnbc and scchn